Manufacturer of Gilteritinib

Gilteritinib (Gilteritinib) is manufactured by AstraZeneca Pharmaceuticals (Astellas Pharma Inc.). AstraZeneca Pharmaceuticals is an internationally renowned pharmaceutical company focused on developing and selling innovative pharmaceutical products, committed to improving patients' quality of life and extending their lives.

Giritinib is an important development result of the company and is used to treat FLT3 (FMS-like tyrosine kinase 3) mutation-positive acute myeloid leukemia (AML), which is a malignant blood disease. FLT3mutations are common mutations in AML patients and lead to abnormal proliferation and growth of leukemia cells. The mechanism of action of giritinib is to control the growth of leukemia cells by inhibiting the activity of FLT3 receptor tyrosine kinase and interfering with abnormal signaling pathways.

The approval and production of giritinib represents an important breakthrough in medicine, providing a new treatment option for those patients with FLT3mutation-positive AML. It can improve patients' survival rate and quality of life under certain circumstances.

Giritinib is currently on the market in China, but it is not included in medical insurance. If patients need it, they can go to the hospital to buy it at their own expense, but the price is very high, about about 35,000 yuan. For specific prices, please consult the local hospital pharmacy. Foreign original drugs of gilitinib are even more expensive. For example, the price of the Hong Kong version of the original drug is around 90,000 yuan, and the European version of the original drug is as high as more than 200,000 yuan, which is simply unaffordable for ordinary patients. But what is gratifying is that there are already foreign generic drugs of giritinib, mainly Laotian generic drugs. The price is about four to five thousand yuan, which is relatively cheap. In terms of drug ingredients, the ingredients of domestic and foreign original gilitinib drugs are basically the same as those of generic drugs.